ALIMTA® (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: A phase II study

Annals of Oncology

Volumn 14, Issue 3, 2003, Pages 455-460

  Smit, E F ^a   Mattson, K ^b   von Pawel, J ^c   Manegold, C ^d   Clarke, S ^e   Postmus, P E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e SYDNEY CANCER CENTRE   (Australia)

Author keywords

Non small cell lung cancer; Pemetrexed; Second line chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; ETOPOSIDE; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM; RALTITREXED; TAXANE DERIVATIVE; TEMOZOLOMIDE; TENIPOSIDE; VINBLASTINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER SURVIVAL; CHOLECYSTITIS; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; DYSPNEA; FATIGUE; FEMALE; FLU LIKE SYNDROME; GRANULOCYTOPENIA; HUMAN; INFECTION; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RASH; RHINITIS; THROMBOCYTOPENIA; DISEASE COURSE; DRUG RESISTANCE; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTAMATES; GUANINE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

EID: 0037352426     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg099     Document Type: Article

References (19)

1. The Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995; 311: 899-909.
2. Cullen MH, Billingham LJ, Woodroffe CM et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17: 3188-3194.
3. Shepherd FA. Chemotherapy for advanced non-small-cell lung cancer: modest progress, many choices. J Clin Oncol 2000; 18: 35-38.
4. Le Chevalier T, Brisgand D, Douillard JY et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-367.
5. Giaccone G, Splinter TAW, Debruyne C et al. Randomized study of paclitaxel-cisplatin versus cisplatin-etoposide in patients with advanced non-small cell lung cancer. J Clin Oncol 1998; 16: 2133-2141.
6. Bonomi P, Kim KM, Fairclough D et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18: 623-631.
7. Choy H, Shyr Y, Cmelak A et al. Patterns of practice survey for non small cell lung carcinoma in the US. Cancer 2000; 88: 1336-1346.
8. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol 2000; 18: 2354-2362.
9. Loh KK, Cohn A, Kelly K et al. Phase II trials of Thymitaq (AG337) in six solid tumor diseases. Proc Am Soc Clin Oncol 1996; 15: 183 (Abstr 385).
10. Heaven R, Bowen K, Rinaldi D et al. An open phase II trial of ZD1694, a thymidylate synthase inhibitor, in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1994; 13: 355 (Abstr 1191).
11. Kris MG, D'Acquisto RW, Gralla RJ et al. Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer. Am J Clin Oncol 1989; 12: 24-26.
12. Selawry O, Krant M, Scotto J et al. Methotrexate compared with placebo in lung cancer. Cancer 1977; 40: 4-8.
13. Clarke S, Boyer M, Milward M et al. Phase II study of LY231514, a multi-targeted antifolate, in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1997; 16: 465a (Abstr 1670).
14. Rusthoven JJ, Eisenhauer E, Butts C et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999; 17: 1194-1199.
15. Fleming TR. One-sample multiple testing procedure for phase 2 clinical trials. Biometrics 1982; 38: 143-151.
16. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
17. Bunn P, Paoletti P, Niyikiza C et al. Vitamin B12 and folate reduce toxicity of ALIMTA (pemetrexed di sodium, LY231514, MTA), a novel antifolate/antimetabolite. Proc Am Soc Clin Oncol 2001; 20: 76a (Abstr 300).
18. Adjei AA. Pemetrexed: a multitargeted antifolate with promising activity in solid tumors. Ann Oncol 2000; 11: 1335-1341.
19. Huisman C, Smit EF, Giaccone G, Postmus PE. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 2000; 18: 3722-3730.